News – Page 1005 – Endpoints News

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

7 years ago

Biotech vets launch a neuro startup with $54.5M to kickstart R&D

7 years ago

Amgen sharpens focus on genetic sequencing with $66M investment

7 years ago

AbbVie frontloads Morphic fibrosis development deal with $100M in cash

7 years ago

FDA slaps down Novartis' blockbuster pitch for canakinumab — so what went wrong?

7 years ago

FDA slaps a full hold on Affimed's T cell engager in wake of a lethal reaction

7 years ago

Giant Pfizer looking to shed close to 2,000 jobs as it crafts a ‘simpler’ management structure

7 years ago

From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout

7 years ago

J&J takes a $630M asset hit on the books, shuttering PhIIb trials as its $1.75B RSV drug teeters on the brink

7 years ago

Eiger chalks up one win, one loss between a pair of PhII rare disease drugs, reshuffling priorities

7 years ago

Novotech beefs up Asia-Pacific CRO offering with new buyout as region’s biopharma business booms

7 years ago

Allergan set to make headway in crowded CGRP migraine market, as the battle for formulary coverage begins

7 years ago

Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs

7 years ago

FDA lists 205 molecular targets for pediatric cancer research

7 years ago

Roche torches a mountain of biobucks, sweeping out a roster of drugs in the latest pipeline cleanup

7 years ago

Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins

7 years ago

Six years after a spectacular debut, Warp Drive Bio is powering down and handing its 'undruggable' ambitions over to ...

7 years ago

Genentech builds new office in Oregon after trimming HQ staff; Researchers laud ketamine as a replacement for opioids

7 years ago

Regeneron, Sanofi talk up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

7 years ago

Pharnext rare disease drug scores in late-stage study, teeing up applications at the FDA and EMA

7 years ago

Guest column: The real cost of drug development

7 years ago

Taiho antes up an extra $250M for its venture arm as it gets serious about 'global oncology' deals

7 years ago

ICER plots early scientific advice program for biopharma

7 years ago

AstraZeneca chairman repeats their position on investing in UK during Brexit talks, triggering fresh fears

7 years ago

First page Previous page 1002 1003 100410051006 1007 1008 Next page Last page